SELLAS Life Sciences Group, Inc.
SLS009
T-cell prolymphocytic leukemia (T-PLL)
Date
TBD
Phase 1 readout · Date TBD estimated
What's at stake
Phase 1 trial results for SLS009 in T-cell prolymphocytic leukemia (T-PLL) are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“These findings further support the therapeutic potential of SLS009 to improve outcomes across multiple hematologic malignancies.”